论文部分内容阅读
观察类风湿性关节炎患者的各种感染性事件,分析与之相关的各种风险因素。方法:这是一个回顾性研究,调查和随访2003年6月—2008年6月5年间在我科接受治疗超过1年以上RA患者,统计其因感染性疾病而住院的事件,收集患者的各种信息,包括性别、年龄、病程、病期、药物、合并疾病等,汇总进行分析。结果:本次研究总共观察98例病人,结果在治疗期间有7例患过急性肺炎,2例患过急性尿路感染,2例患过软组织感染,1例患过化脓性关节炎,1例患过III型肺结核,1例患过PCP肺炎,肺部感染总数9例,与其他部位感染人数比较均P<0.05,差异有显著性;治疗3年以上患者的感染率与治疗3年以下的感染率比较P<0.05,差异有显著性;感染组患者的强地松和甲氨喋呤的服用剂量与未感染组比较,P均<0.05,差异有显著性,此外感染组的年龄、病程与未感染组比较P均<0.05,差异有显著性。结论:①研究表明在治疗RA的长期过程中,遭受肺部感染的风险最高。②RA患者感染风险与强地松和甲氨喋呤的服用剂量和持续时间以及患者的年龄和病程成正相关关系。
Observe various infectious events in patients with rheumatoid arthritis and analyze the various risk factors associated with them. METHODS: This is a retrospective study, survey, and follow-up. Patients with RA who were treated in our department for more than 1 year between June 2003 and June 2008 were enrolled in the study. All patients were admitted to hospital for infectious diseases. Kinds of information, including gender, age, duration, duration of illness, drugs, combined diseases, etc., summarized for analysis. Results: A total of 98 patients were observed in this study. Results Seven patients had acute pneumonia, two had acute urinary tract infection, two had soft tissue infections, one had septic arthritis and one had septic arthritis One patient had PCP pneumonia and the total number of pulmonary infection was 9 cases, which was significantly different from that of other sites in all cases (P <0.05), and the difference was significant. The infection rate of patients with more than 3 years of treatment was lower than that of patients treated with 3 years The infection rate of P <0.05, the difference was significant; Infected group of patients with prednisone and methotrexate dose and uninfected group, P <0.05, the difference was significant, in addition to the infection group’s age and duration Compared with non-infected group P <0.05, the difference was significant. Conclusions: (1) Studies have shown that the risk of lung infection is highest during the long-term treatment of RA. ② The risk of RA infection was positively related to the dose and duration of prednisone and methotrexate, as well as the patient’s age and duration.